# Arvelle Therapeutics International

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arvelle-therapeutics-international

- Industry: Biotechnology
- Headquarters: Zug, Switzerland
- Website: www.arvelletx.com
- Total disclosed funding: $217M
- Latest round: Series A (May 26, 2020)
- Investors on record: 7

## About

Arvelle Therapeutics International GmbH, based in Zug, Switzerland, is a biopharmaceutical company focused on developing innovative therapies for patients with central nervous system disorders. The company aims to address unmet medical needs in this therapeutic area.Arvelle Therapeutics International GmbH specializes in the development of treatments for central nervous system conditions. Founded in 2019 in Zug, Switzerland, the company has undergone a significant transition in its corporate strategy. In January 2021, Arvelle was acquired by Angelini Pharmaceuticals for USD 610 mn in cash, with potential for an additional USD 350 mn contingent on revenue milestones. This acquisition highlights the strategic value of Arvelle's portfolio, which aligns with Angelini's therapeutic interests. The company has completed a total of 4 deals as of its most recent deal date.Arvelle Therapeutics International GmbH focuses on developing advanced therapeutics aimed at treating central nervous system disorders. Their lead product is designed to improve the quality of life for patients suffering from epilepsy and related conditions, offering a novel mechanism of action compared to existing treatments. This innovative approach addresses critical needs within the therapeutic landscape, enhancing care for patients.Arvelle Therapeutics International GmbH has raised a total of USD 610 mn to date, following its latest funding round which involved a TRADE SALE to Angelini Pharmaceuticals. This financial backing is expected to support the advancement of their key therapies and expand their research capabilities.Looking ahead, Arvelle Therapeutics International GmbH plans to leverage its latest funding from the acquisition to enhance its product development pipeline and expand its market presence. The company aims to introduce new therapies for central nervous system disorders and is exploring opportunities for market expansion throughout Europe and North America. The strategic direction focuses on utilizing the resources from the TRADE SALE to accelerate research and development efforts, with anticipated launches in the upcoming years, further solidifying its position in the biopharmaceutical landscape.

## Funding rounds

- Series A, May 26, 2020, $38M — Andera Partners, EQT Life Sciences, H.I.G. BioHealth Partners, F-Prime Capital, KB Securities, NovaQuest Capital Management, BRV Capital Management
- Series A, Feb 15, 2019, $179M — Andera Partners, EQT Life Sciences, H.I.G. BioHealth Partners, NovaQuest Capital Management, BRV Capital Management

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series A
- NovaQuest Capital Management (https://capitalatlas.ai/funds/novaquest-capital-management) — Series A
- BRV Capital Management (https://capitalatlas.ai/funds/brv-capital-management) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series A